Immix Biopharma, Inc.

NasdaqCM IMMX

Immix Biopharma, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -970.67%

Immix Biopharma, Inc. Gross Profit Margin is -970.67% for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: IMMX

Immix Biopharma, Inc.

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends

Past 5 years